ArticlePatient preference and adherence2025
Identification and Rating of Treatment Goals in Schizophrenia: Delphi Process and Concordance Survey in Matched Physician-Patient Pairs.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Scoping Review of Methods, Guidelines, and Protocols Used for Dose Reduction or Discontinuation of Antipsychotic Medication in People Affected by Psychotic Disorders.Schizophrenia bulletin · 2026Article
- Treatment Goals in Schizophrenia as Seen by Matched Patients and Physicians: Preferences and Medication Formulation Strategies.Neuropsychiatric disease and treatment · 2026Article
- Treatment Goals in Schizophrenia: Subgroup Analysis of a Survey in Matched Physician-Patient Pairs.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ratings of treatment goals for patients with schizophrenia have been studied in both patients and physicians. However, in most studies so far, treatment goals were assessed either by psychiatrists or by patients, but not by both for an individual patient case. Therefore, our study assessed treatment goals from matched physician-patient pairs. Methods: First, an expert panel created a questionnaire with treatment goals, based on a systematic literature search. These goals were rated for their relevance in the treatment of schizophrenia by 24 independent psychiatrists. In the second part of the study, questionnaires were sent to psychiatrists all over Germany. Psychiatrists were asked to rate treatment goals for up to 3 specific patients. Furthermore, these same patients were asked to rate the goals for themselves. Results: In the first part of the study, the 24 psychiatrists agreed that 30 out of 31 treatment goals chosen by the expert panel were relevant. In the second part, effectiveness and quality of life were more often seen as the most important treatment goal categories than tolerability by both patients and physicians in matched pairs of 80 patients and 28 physicians. There was a substantial agreement between physicians and patients. However, patients expressed apprehension about possible side effects of the medication, a concern not recognized in its extent by physicians. Patients also prioritized treatment goals related to tasks of daily life and coping with illness, whereas physicians put greater emphasis on preventing relapses and re-hospitalizations. Conclusion: We found that experts agree upon the importance of 30 treatment goals from three categories. Physicians and patients largely align on treatment goals. More emphasis may be placed on clarifying potential medication side effects. Physicians should be aware that patients' priorities could be more focused on improving quality of life and gaining autonomy rather than symptom management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.